This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $639,790 to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to conduct research on the epigenetic and metabolic regulation of tumor dormancy and recurrence in metastatic breast cancer. The key research objectives are to: 1) determine how histone H3.3 deposition and chromatin remodeling by the HIRA complex regulate the transition between dormant and proliferative states in disseminated breast cancer cells; 2) precisely define the metabolic and redox requirements at critical inflection points in the metastatic cascade; and 3) elucidate the role of the HIRA-H3.3 axis in mediating interactions between the lung microenvironment and the fate of dormant cancer cells. The research aims to uncover HIRA as a therapeutic target to prevent reawakening and recurrence of metastatic breast cancer, as well as identify metabolic vulnerabilities of dormant tumor cells. The award period is from July 2024 through June 2029.
Generated 2/25/25, 2:44 AM